A novel CDK12 inhibitor induces homologous recombination deficiency to enhance PARP inhibitor efficacy in uterine serous carcinoma [0.03%]
一种新型CDK12抑制剂通过诱导同源重组缺陷增强PARP抑制剂在子宫浆液性癌中的疗效
Shunsuke Kawahara,Mana Taki,Junzo Hamanishi et al.
Shunsuke Kawahara et al.
Uterine serous carcinoma (USC) is an aggressive p53-mutated endometrial carcinoma that exhibits gene mutations in homologous recombination (HR) pathways, similar to high-grade serous ovarian carcinoma (HGSOC). However, the therapeutic effec...
Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness [0.03%]
探索前列腺癌DNA损伤修复治疗靶点 Beyond BRCAness
Fabrizio Di Costanzo,Jack Williamson,Craig N Robson et al.
Fabrizio Di Costanzo et al.
Prostate cancers harboring alterations of genes involved in DNA damage response and repair tend to be more aggressive and are associated with poorer survival outcomes. The application of poly (ADP-ribose) polymerase (PARP) enzyme inhibitors...
Distinct H3K27 methylation states drive cellular responses to the histone demethylase inhibitor GSK-J4 in ovarian cancer cells [0.03%]
组蛋白去甲基化酶抑制剂GSK-J4通过不同的H3K27甲基化状态驱动卵巢癌细胞的生物学反应
Marcos Quintela,Lydia C Powell,Agne Baseviciene et al.
Marcos Quintela et al.
The deregulation of histone methylation has been implicated in the pathogenesis of multiple diseases, including ovarian cancer (OC), one of the most lethal gynaecological malignancies worldwide. The roles of the H3K27 demethylases UTX and J...
αvβ3 CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer [0.03%]
针对肿瘤和转移灶的αvβ3 CAR-T细胞在黑色素瘤和三阴性乳腺癌的临床前模型中产生有效的控制作用
Dustin A Cobb,Philip Mollica rd,Lixia Liu et al.
Dustin A Cobb et al.
One of the many barriers to successful chimeric antigen receptor (CAR) T-cell immunotherapy against solid tumors is the scarcity of targetable molecules common to multiple types of cancer. The purpose of this study was to determine the effi...
Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours [0.03%]
Capivasertib联合T-DXd可增强HER2阳性及低表达肿瘤的抗肿瘤活性
Azadeh C Bashi,Theresa A Proia,Mandy Lawson et al.
Azadeh C Bashi et al.
Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor, is approved for the treatment of HER2-positive and HER2-low breast cancer as well as HER2-high gastric a...
M6 metabolite contributes to the efficacy of the Rac/Cdc42 inhibitor MBQ-167 in metastatic breast cancer [0.03%]
M6代谢物有助于Rac/Cdc42抑制剂MBQ-167治疗转移性乳腺癌的疗效
Nilmary Grafals-Ruiz,Julia I Medina,Jessica Colon Gonzalez et al.
Nilmary Grafals-Ruiz et al.
Metastasis remains a major challenge in cancer treatment due to the lack of effective targeted therapies. MBQ-167, a first-in-class dual Rac/Cdc42 inhibitor currently in a Phase 1 clinical trial, has demonstrated promising activity in precl...
Kathryn Shimamoto,Diren Arda Karaoglu,Olivia Arnold et al.
Kathryn Shimamoto et al.
T-lineage acute lymphoblastic leukemia (T-ALL) lacks effective targeted therapies, with poor outcomes in relapsed/refractory disease. HOXA-high T-ALL is biologically aggressive and often resistant to standard therapy. Menin inhibitors, rece...
Targeting Semaphorin 7a signaling in preclinical models of endocrine therapy-resistant breast cancer [0.03%]
靶向分泌素7a信号对抗内分泌治疗耐药性乳腺癌的前临床模型的研究
Rachel N Steinmetz,Veronica Wessells,Heather Fairchild et al.
Rachel N Steinmetz et al.
Estrogen receptor-positive (ER+) breast cancers (BC) comprise over 70% of breast cancers and are the leading cause of BC-related deaths in women worldwide. Despite available therapies that target ER, recurrence occurs in many patients due t...
JNJ-79032421, a Novel Membrane-restricted Mesothelin-targeting T-cell-engaging Bispecific Antibody for the Treatment of Mesothelin-positive Cancers [0.03%]
针对叶酸受体α的抗体药物偶联物SHR-A1201用于治疗实体瘤的安全性、耐受性和有效性Ib期临床试验
Karine Smans,Thomas Nesspor,Sabine De Breucker et al.
Karine Smans et al.
Mesothelin (MSLN) is a cell-membrane-anchored glycoprotein overexpressed in several cancers including pancreatic cancer, ovarian cancer, and mesothelioma. MSLN is protease-cleaved at the membrane-proximal region, releasing shed MSLN (sMSLN)...
Expression of Concern: ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance [0.03%]
表达关切：ATM 和 p53 通过 E2F调节乳腺癌中表柔比星治疗和耐药的FOXM1 表达
Julie Millour,Natalia de Olano,Yoshiya Horimoto et al.
Julie Millour et al.